CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial

Abstract

Authors

M. Sekeres V. Santini M. Diez-Campelo R. Komrokji P. Fenaux M. Savona Y. Madanat D. Valcárcel-Ferreiras T. Illmer A. Jonášová P. Bělohlávková A. Regnault K. Creel N. Sengupta L. Sherman T. Berry S. Dougherty S. Shah Q. Xia L. Sun Y. Wan F. Huang A. Ikin S. Navada F. Feller A. Zeidan U. Platzbecker

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×